The Challenges Of Valuing Litigation-Driven Equities

Law360 (August 30, 2018, 12:34 PM EDT) -- Many eyes are on the Delaware Court of Chancery to see whether it will compel Fresenius SE to close on a $4.5 billion acquisition of generic drugmaker Akorn Inc. Fresenius terminated the merger agreement in April 2018 and Akorn sued immediately. The parties engaged in expedited discovery, went to trial in July, and completed post-trial briefing last week.

Fresenius argues it can break the deal because Akorn breached its obligations to comply with U.S. Food and Drug Administration regulations and that a "material adverse effect" exists. Akorn says that Fresenius developed a strategy to prod the FDA into launching investigations of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!